Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3104
- TODAY'S CHANGE (%)0.0214 (7.4048%)
- Bid / Lots0.3051/ 19
- Ask / Lots0.3195/ 12
- Open / Previous Close0.2910 / 0.2890
- Day Range
- 52 Week Range
- Volume1,808,274
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 20928 | 0.2986 |
| 09:34 ET | 100 | 0.2972 |
| 09:36 ET | 1216 | 0.2972 |
| 09:38 ET | 1000 | 0.2972 |
| 09:39 ET | 2250 | 0.298 |
| 09:41 ET | 758 | 0.2973 |
| 09:43 ET | 16594 | 0.289 |
| 09:45 ET | 84111 | 0.2821 |
| 09:48 ET | 1000 | 0.289832 |
| 09:50 ET | 399 | 0.291 |
| 09:57 ET | 30200 | 0.295 |
| 09:59 ET | 250 | 0.29 |
| 10:01 ET | 9110 | 0.2946 |
| 10:03 ET | 101 | 0.2867 |
| 10:10 ET | 50130 | 0.2868 |
| 10:14 ET | 100 | 0.2909 |
| 10:15 ET | 6084 | 0.2868 |
| 10:17 ET | 6607 | 0.2892 |
| 10:19 ET | 1509 | 0.295 |
| 10:21 ET | 6694 | 0.295 |
| 10:24 ET | 1165 | 0.295 |
| 10:26 ET | 1098 | 0.295 |
| 10:28 ET | 2051 | 0.295 |
| 10:30 ET | 9067 | 0.295 |
| 10:32 ET | 5318 | 0.295 |
| 10:33 ET | 700 | 0.295 |
| 10:35 ET | 1350 | 0.2923 |
| 10:37 ET | 750 | 0.295 |
| 10:39 ET | 5471 | 0.295 |
| 10:42 ET | 500 | 0.295 |
| 10:44 ET | 700 | 0.295 |
| 10:46 ET | 500 | 0.295 |
| 10:48 ET | 500 | 0.295 |
| 10:50 ET | 1500 | 0.295 |
| 10:51 ET | 1420 | 0.295 |
| 10:53 ET | 500 | 0.295 |
| 10:55 ET | 2900 | 0.2923 |
| 10:57 ET | 22924 | 0.2893 |
| 11:00 ET | 7203 | 0.295 |
| 11:02 ET | 2400 | 0.295 |
| 11:04 ET | 1300 | 0.295 |
| 11:06 ET | 13100 | 0.2903 |
| 11:09 ET | 10300 | 0.295 |
| 11:11 ET | 10000 | 0.2894 |
| 11:13 ET | 8000 | 0.2901 |
| 11:15 ET | 2100 | 0.2901 |
| 11:18 ET | 300 | 0.295 |
| 11:22 ET | 300 | 0.295 |
| 11:24 ET | 780 | 0.295 |
| 11:26 ET | 2225 | 0.2925 |
| 11:27 ET | 400 | 0.2949 |
| 11:29 ET | 700 | 0.2949 |
| 11:31 ET | 1623 | 0.2911 |
| 11:33 ET | 400 | 0.2949 |
| 11:36 ET | 2715 | 0.2902 |
| 11:38 ET | 400 | 0.2949 |
| 11:40 ET | 58620 | 0.295 |
| 11:42 ET | 377 | 0.295 |
| 11:44 ET | 2400 | 0.295 |
| 11:45 ET | 9948 | 0.291701 |
| 11:49 ET | 38640 | 0.2917 |
| 11:51 ET | 800 | 0.295 |
| 11:54 ET | 400 | 0.295 |
| 11:56 ET | 300 | 0.295 |
| 11:58 ET | 63069 | 0.295 |
| 12:00 ET | 4989 | 0.295 |
| 12:02 ET | 500 | 0.295 |
| 12:03 ET | 54414 | 0.299 |
| 12:05 ET | 93161 | 0.3035 |
| 12:07 ET | 57885 | 0.305 |
| 12:09 ET | 9035 | 0.305 |
| 12:12 ET | 11538 | 0.305 |
| 12:14 ET | 23513 | 0.3139 |
| 12:16 ET | 19266 | 0.308049 |
| 12:18 ET | 15000 | 0.307516 |
| 12:20 ET | 4990 | 0.308 |
| 12:21 ET | 43122 | 0.314 |
| 12:23 ET | 27907 | 0.3177 |
| 12:25 ET | 23739 | 0.314 |
| 12:27 ET | 6240 | 0.3116 |
| 12:30 ET | 23136 | 0.3157 |
| 12:32 ET | 48669 | 0.316 |
| 12:34 ET | 3536 | 0.314 |
| 12:36 ET | 132136 | 0.31845 |
| 12:38 ET | 21582 | 0.3106 |
| 12:39 ET | 500 | 0.3101 |
| 12:41 ET | 1339 | 0.3106 |
| 12:43 ET | 20873 | 0.3199 |
| 12:45 ET | 469 | 0.3189 |
| 12:48 ET | 313 | 0.316 |
| 12:50 ET | 6046 | 0.3102 |
| 12:52 ET | 6509 | 0.3151 |
| 12:54 ET | 1056 | 0.3159 |
| 01:01 ET | 1494 | 0.3152 |
| 01:03 ET | 1779 | 0.3198 |
| 01:06 ET | 5000 | 0.3198 |
| 01:08 ET | 500 | 0.3195 |
| 01:12 ET | 5850 | 0.3111 |
| 01:14 ET | 240 | 0.3184 |
| 01:15 ET | 17238 | 0.317 |
| 01:17 ET | 10133 | 0.3151 |
| 01:19 ET | 611 | 0.3173 |
| 01:24 ET | 6190 | 0.3195 |
| 01:28 ET | 3800 | 0.3195 |
| 01:30 ET | 1911 | 0.3143 |
| 01:35 ET | 30847 | 0.3133 |
| 01:37 ET | 15073 | 0.3113 |
| 01:39 ET | 500 | 0.3125 |
| 01:44 ET | 21066 | 0.3102 |
| 01:46 ET | 200 | 0.3101 |
| 01:48 ET | 1400 | 0.3102 |
| 01:50 ET | 100 | 0.3101 |
| 01:51 ET | 1650 | 0.3101 |
| 01:53 ET | 2000 | 0.3101 |
| 01:55 ET | 100 | 0.3102 |
| 01:57 ET | 1000 | 0.3145 |
| 02:02 ET | 10000 | 0.3168 |
| 02:09 ET | 500 | 0.3168 |
| 02:11 ET | 5000 | 0.3102 |
| 02:15 ET | 2220 | 0.3102 |
| 02:22 ET | 500 | 0.3125 |
| 02:26 ET | 900 | 0.3102 |
| 02:29 ET | 10919 | 0.3128 |
| 02:36 ET | 3000 | 0.3103 |
| 02:38 ET | 500 | 0.3103 |
| 02:44 ET | 3505 | 0.3103 |
| 02:45 ET | 431 | 0.315999 |
| 02:49 ET | 5000 | 0.314 |
| 02:51 ET | 15190 | 0.3122 |
| 02:54 ET | 1300 | 0.3133 |
| 02:58 ET | 100 | 0.3111 |
| 03:02 ET | 1300 | 0.315 |
| 03:03 ET | 1478 | 0.313051 |
| 03:05 ET | 2700 | 0.3128 |
| 03:14 ET | 11684 | 0.3104 |
| 03:16 ET | 330 | 0.31035 |
| 03:18 ET | 2000 | 0.310301 |
| 03:21 ET | 8200 | 0.3104 |
| 03:23 ET | 1000 | 0.3114 |
| 03:25 ET | 16819 | 0.3101 |
| 03:27 ET | 1000 | 0.3103 |
| 03:30 ET | 570 | 0.3104 |
| 03:36 ET | 18471 | 0.3101 |
| 03:38 ET | 819 | 0.3106 |
| 03:39 ET | 436 | 0.3105 |
| 03:43 ET | 1810 | 0.3106 |
| 03:45 ET | 1390 | 0.311 |
| 03:48 ET | 300 | 0.3105 |
| 03:54 ET | 3762 | 0.3104 |
| 03:56 ET | 200 | 0.3105 |
| 03:57 ET | 262 | 0.3105 |
| 03:59 ET | 25639 | 0.3104 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 15.9M | -0.2x | --- |
Turnstone Biologics Corp | 11.0M | -0.1x | --- |
Viaderma Inc | 10.6M | 0.0x | --- |
SQZ Biotechnologies Co | 678.3K | 0.0x | --- |
Celularity Inc | 34.7M | -0.2x | --- |
ImmuCell Corp | 28.7M | -6.9x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
- Director
- Helen Boudreau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.9M |
|---|---|
Revenue (TTM) | $11.0M |
Shares Outstanding | 54.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-2.04 |
Book Value | $1.05 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,000.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
